Elranatamab versus physician’s choice of treatment in patients with triple-class exposed/refractory multiple myeloma: an updated matching-adjusted indirect comparison

Aim: Despite the availability of novel treatment options for patients with triple-class exposed/refractory multiplemyeloma , there is a lack of consensus on the optimal regimen. A previous unanchored matchingadjusted indirect comparison (MAIC) of the MagnetisMM-3 (NCT04649359) and LocoMMotion (NCT...

Volledige beschrijving

Bibliografische gegevens

Hoofdauteurs:	Isha Mol, Yannan Hu, Thomas W LeBlanc, Joseph C Cappelleri, Haitao Chu, Guido Nador, Didem Aydin, Isabel Perez Cruz, Patrick Hlavacek
Formaat:	Artigo
Taal:	Inglês
Gepubliceerd in:	Becaris Publishing Limited 2025-04-01
Reeks:	Journal of Comparative Effectiveness Research
Onderwerpen:	elranatamab locommotion magnetismm-3 matching-adjusted indirect comparison physician’s choice of treatment triple-class exposed/refractory multiple myeloma
Tags:	Voeg label toe Geen labels, Wees de eerste die dit record labelt!